May 23, 2017: Here are four stocks trading with relatively heavy volume among 88 equities making new 52-week lows in Tuesday’s session. On the NYSE, advancers led decliners by about 4 to 3 and on the Nasdaq advancers led decliners by about the same margin.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) posted a new 52-week low of $102.47 on Tuesday, down more than 11% compared with Monday’s closing price of $115.42. The stock’s 52-week high is $157.02. Volume totaled more than 16 million shares, nearly 6 times the daily average of about 3 million. The company announced several executive changes this morning.
Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) dropped about 3.3% Tuesday to post a new 52-week low of $28.48 after closing at $29.44 on Monday. The stock’s 52-week high is $56.44. Volume of about 12.3 million was about 70% above the daily average of around 8 million shares traded. The company had no specific news.
Cerus Corp. (NASDAQ: CERS) dropped about 27% Tuesday to post a new 52-week low of $2.19 after closing at $3.00 on Monday. The stock’s 52-week high is $7.64. Volume was about 5 times the daily average of around 1.6 million shares. The company had no specific news.
DSW Inc. (NYSE: DSW) dropped about 9.5% Tuesday to post a new 52-week low of $15.98 after closing Monday at $17.65. The 52-week high is $26.22. Volume of around 6.3 million shares was about 2.5 times the daily average. The footwear and accessories company reported first-quarter earnings that were below estimates.
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
